Position of the Transparency Council – Olumiant (baricitinibum)

At its Meeting on 23 May 2022, the Transparency Council adopted Position No. 49/2022 on the evaluation of Olumiant (baricitinibum) under the drug programme: : “Treatment of patients with severe and moderate forms of atopic dermatitis (ICD-10: L20)”.

Publication in Public Information Bulletin (BIP)